High Altitude Illness - AMS HACE HAPE Management

Key Points

• Stop ascent whenever acute altitude illness develops.
• Fitness does not protect against AMS, HACE, or HAPE.
• Ataxia or altered mental status at altitude is HACE until proven otherwise.
• Dyspnea at rest and reduced oxygenation with pulmonary findings suggest HAPE.
• Immediate descent and oxygen are the central treatments for HACE and HAPE.
• Dexamethasone treats HACE; acetazolamide is most useful for acclimatization and AMS prevention or treatment.
• Nifedipine is an important HAPE medication when descent or oxygen is limited and for selected prophylaxis.
• Portable hyperbaric bags are temporary bridges when definitive descent is delayed.

Algorithm

1. Identify recent altitude gain and compare symptoms with the ascent timeline.
2. For mild AMS, stop ascent, rest, and treat symptoms; consider acetazolamide.
3. If symptoms worsen or fail to improve, descend.
4. If ataxia, confusion, or altered consciousness develops, treat as HACE with descent, oxygen, and dexamethasone.
5. If dyspnea at rest or pulmonary edema develops, treat as HAPE with descent and oxygen.
6. Use nifedipine for HAPE when appropriate and portable hyperbaric therapy when descent or oxygen is temporarily unavailable.
7. Evacuate severe cases and evaluate for competing diagnoses if recovery is atypical.
8. Plan slower future ascent and individualized prophylaxis after recovery.

Clinical Synopsis & Reasoning

Acute mountain sickness typically develops within hours after ascent to altitude and is characterized by headache plus symptoms such as nausea, dizziness, fatigue, or sleep disturbance. Symptoms generally follow a recent gain in sleeping elevation. The diagnosis is clinical; there is no laboratory test that confirms uncomplicated AMS. A traveler with isolated headache should still be evaluated for dehydration, migraine, carbon monoxide exposure, infection, and other causes, but altitude context and symptom pattern are central.

HACE represents severe cerebral altitude illness. Ataxia, confusion, altered consciousness, marked lassitude, or neurologic deterioration in a person at altitude should be treated as HACE until proven otherwise. It can evolve from AMS but may appear without a long prodrome. HAPE is noncardiogenic pulmonary edema caused by uneven hypoxic pulmonary vasoconstriction. Early clues include disproportionate exertional dyspnea, reduced exercise tolerance, cough, tachycardia, and low oxygen saturation for the altitude; progression produces dyspnea at rest, crackles, cyanosis, and respiratory failure. HACE and HAPE can coexist.

Risk is determined more by ascent profile and prior susceptibility than by fitness. The 2024 WMS guidance emphasizes limiting sleeping-elevation gain above 3000 m to roughly 500 m per day and adding a rest day every 3 to 4 days when feasible. Pulse oximetry can support evaluation but normal values are altitude-dependent and a single saturation cannot exclude illness. Improvement with descent or oxygen supports the diagnosis but treatment should not wait for a diagnostic trial in a deteriorating patient.

Treatment Strategy & Disposition

For mild AMS, stop ascent, rest, treat headache and nausea, and consider acetazolamide. Further ascent should not occur until symptoms have resolved. Descent is the definitive treatment for worsening AMS. Acetazolamide accelerates acclimatization through carbonic anhydrase inhibition and is also used prophylactically for moderate- or high-risk ascent. Dexamethasone improves symptoms and is useful for treatment or prophylaxis when acetazolamide cannot be used, but it does not facilitate acclimatization in the same way.

HACE requires immediate descent, supplemental oxygen to improve hypoxemia, and dexamethasone. A portable hyperbaric chamber can be used when descent or oxygen is temporarily impossible, but it is a bridge and should not delay evacuation. Keep the patient from exerting themselves during descent when possible.

HAPE also requires immediate descent and oxygen. Rest and avoidance of exertion are important. Nifedipine can reduce pulmonary artery pressure and is used particularly when descent or adequate oxygen is not immediately available, as well as for prophylaxis in highly susceptible people. Phosphodiesterase-5 inhibitors are alternative preventive or treatment adjuncts in selected circumstances but are not substitutes for descent and oxygen. Diuretics are not routine treatment because patients are not suffering from volume-overload heart failure. After HACE or HAPE, future ascent planning should be individualized because recurrence risk is substantial.

Epidemiology / Risk Factors

• Risk rises with rapid ascent, high sleeping altitude, and prior altitude illness.
• Very fit individuals remain susceptible because conditioning does not accelerate acclimatization.
• AMS is common among rapid travelers to elevations above roughly 2500 m.
• HACE and HAPE are less common but can be fatal without descent and oxygen.

Investigations

Medication Roles

Pharmacology

Prognosis / Complications

• Mild AMS usually resolves with rest at the same altitude or descent.
• HACE and HAPE can improve rapidly after descent and oxygen if treated early.
• Delay after neurologic or resting respiratory symptoms increases mortality risk.
• A prior episode of HAPE or HACE markedly increases recurrence risk during future rapid ascents.

Patient Education / Counseling

• Above 3000 m, increase sleeping elevation gradually, generally no more than about 500 m per day when feasible.
• Include an acclimatization rest day every 3 to 4 days during continued ascent.
• Do not use physical fitness as a reason to accelerate ascent.
• Know that new ataxia, confusion, or dyspnea at rest requires descent rather than continued observation.
• Discuss acetazolamide or other prophylaxis before trips when prior history or itinerary places the traveler at moderate or high risk.

Notes

Altitude illness is fundamentally a problem of inadequate acclimatization to hypobaric hypoxia. The treatment hierarchy therefore differs from many sea-level illnesses: lowering altitude and increasing inspired oxygen address the cause directly.

The 2024 WMS update continues to emphasize ascent profile as the most modifiable risk factor. A medication can reduce risk, but it should not be used to justify an unnecessarily rapid itinerary.

References

1. Wilderness Medical Society 2024 Altitude Summary — Link
2. Wilderness Medical Society Clinical Practice Guidelines and Summaries — Link